Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Clascoterone is a non-peptide steroidal topical androgen receptor antagonist—a 17α-propionate ester of cortexolone (11-deoxycortisol). Winlevi (clascoterone 1% cream) is FDA-approved (2020) for topical treatment of acne vulgaris in patients 12 years and older. A higher-strength 5% topical solution (Breezula) has completed Phase 3 trials for male androgenetic alopecia but remains investigational for that indication. Despite established androgen-receptor binding, the FDA label states the mechanism of action for acne treatment is unknown.
0 of 1 vendors lab-verified
Verified purity per dollar — the cheapest that's actually been tested
No prices found for Clascoterone (CB-03-01).
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
Kimera Chems has the lowest single-vial Clascoterone (CB-03-01) price at $0.068/mg among 1 COA-verified vendor on Disclosed Labs. Bulk or multi-vial deals may be lower.
What is the price range for Clascoterone (CB-03-01)?
Research-grade Clascoterone (CB-03-01) is listed at $0.068/mg from 1 verified source on Disclosed Labs.
How are Clascoterone (CB-03-01) prices verified on Disclosed Labs?
Every listed vendor holds a Grade C or better trust score, computed independently from lab Certificates of Analysis — not from payments or sponsorships. Prices are scraped and fact-checked daily. Vendors cannot pay to improve their ranking.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
Clascoterone is an FDA-approved prescription drug. Winlevi (clascoterone 1% cream) was approved in 2020 for topical treatment of acne vulgaris in patients 12 years of age and older, based on two identical Phase 3 RCTs (NCT02608450, NCT02608476; n=1421, ages 12+) showing IGA success rates of 18.8% and 20.9% for clascoterone vs. 8.7% and 6.6% for vehicle at Week 12. A separate, higher-strength 5% topical solution (Breezula) has completed a Phase 3 trial (SCALP2, NCT05914805, actual enrollment 762) for male androgenetic alopecia; this indication is investigational/unapproved. In hamster flank-organ models (topical antiandrogen bioassay), CB-03-01 showed strong local antiandrogenic activity—roughly 4× more potent than progesterone, ~3× more potent than flutamide, ~2× more potent than finasteride, and approximately equipotent with cyproterone acetate (Celasco et al., 2004, PMID 15646372). In rat subcutaneous injection and parabiotic rat models, no systemic antiandrogenic activity was observed, supporting a peripherally-selective (non-systemic) antiandrogen profile (Celasco et al., 2004). In human primary sebocyte cultures (in vitro), clascoterone dose-dependently suppressed lipid synthesis and inflammatory cytokine production, significantly outperforming spironolactone at inhibiting inflammatory cytokine synthesis (Rosette et al., 2019, PMID 31141847).
This platform provides informational tools only, not medical advice.
WINLEVI (clascoterone) Cream, 1% — Highlights of Prescribing Information
2022
Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist
2004
Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro
Prices verified as of July 2026. Actual prices may vary. For research use only.
2019